Trenton, NJ (PRWEB) April 10, 2013
As a new Fosamax femur fracture trial proceeds in Trenton, N.J., the jury has heard from the plaintiff’s lawyer that manufacturer Merck knew about bone injury risks associated with Fosamax at least five years before the U.S. Food and Drug Administration approved the drug.* The Rottenstein Law Group, which represents clients in Fosamax lawsuits, has been monitoring Fosamax trials and provides updates at http://www.fosamaxlawsuitscenter.com.
The lawyer for plaintiff Bernadette Glynn told a jury in a federal court (Glynn v. Merck & Co., 3:11-cv-05304, U.S. District Court for the District of New Jersey) that in 1990 consultants had warned Merck that the drug could prevent the body’s daily repair of “micro fractures,” according to Bloomberg. New Jersey-based Merck faces more than 3,000 femur fracture lawsuits (in addition to more than 1,200 lawsuits over jawbone death claims), the article said.
“This could be the first trial for a Fosamax femur fracture lawsuit in which there is a jury verdict,” said Rochelle Rottenstein, principal of the Rottenstein Law Group. “In his opening statement the plaintiff’s lawyer promised bombshell evidence supporting the plaintiff’s claims. We look forward to hearing that testimony.”
According to Bloomberg, Glynn, of Cohoes, N.Y., suffered the fall in 2009 and filed her lawsuit against Fosamax manufacturer Merck in late 2011.**
Fosamax, its generic equivalent and other similar bisphosphonate drugs are prescribed to treat osteoporosis. In 2010, according to Bloomberg, a study published in the Journal of Bone and Mineral Research found that the drug, approved in 1995, could be linked to an increase in femur fractures.
Nationwide Fosamax lawsuits were categorized into two different federal pretrial case consolidations for efficiency purposes. Cases involving alleged femur fractures are handled in the U.S. District Court for the District of New Jersey (MDL-2243). Lawsuits related to Fosamax’s alleged jaw death side effects are being handled in the U.S. District Court for the Southern District of New York (MDL-1789).
The Rottenstein Law Group represents clients who believe they have been harmed by Fosamax and encourages people to visit the firm’s Fosamax lawsuits site for more news on trials and comprehensive information about the drug.
About THE ROTTENSTEIN LAW GROUP
The Rottenstein Law Group is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)
The Rottenstein Law Group, LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com